PRODUCT MONOGRAPH

PrVISKEN®
(pindolol tablets U.S.P.)
Tablets 5, 10 and 15 mg

Antihypertensive / Antianginal agent

Tribute Pharmaceuticals Canada Inc.
London, Ontario N5W 3Z8

DATE OF PREPARATION:
July 23, 2015

Control No: 185880
NAME OF DRUG

\(^{\text{P}}\text{VISKEN®}\)
(pindolol tablets U.S.P.)
Tablets 5, 10 and 15 mg

THERAPEUTIC CLASSIFICATION

Antihypertensive/Antianginal Agent

ACTIONS

VISKEN® (pindolol) is a \(\beta\)-adrenergic-receptor-blocking agent which possesses partial agonist activity (intrinsic sympathomimetic activity - I.S.A.). It is used in the treatment of hypertension and/or the prophylaxis of angina pectoris.

Hypertension
The mechanism of the antihypertensive effect of pindolol has not been established. Among the factors that may be involved are:

a) competitive ability to antagonize catecholamine-induced tachycardia at the \(\beta\)-receptor sites in the heart, thus decreasing cardiac output
b) a reduction in total peripheral resistance
c) inhibition of the vasomotor centres
d) inhibition of renin release by the kidneys

Angina Pectoris
The mechanism of the antianginal effect of pindolol has not been established. VISKEN® may reduce the oxygen requirement of the heart at any level of effort by blocking catecholamine-induced increases in the heart rate, systolic blood pressure, and the velocity and extent of myocardial contraction. However, oxygen requirements may be increased by such actions as increases in left ventricular fibre length, end diastolic pressure and the systolic ejection period.
When the net effect is beneficial in patients with angina, it manifests itself during exercise or stress by delaying the onset of pain and reducing the incidence and severity of anginal attacks.

In man, orally-administered pindolol is rapidly and almost completely absorbed (≥95%) from the gastrointestinal tract. The mean absolute bioavailability after oral administration is about 87-92%. Plasma levels of 10 to 30 nanogram/mL are associated with its therapeutic efficacy. Following single dose administration 5 mg pindolol, the mean maximum plasma concentration (Cmax) of pindolol was 33.1 ± 5.2 nanogram/mL (Tmax 1-2 h). The elimination rate of pindolol is not dose dependent. The elimination half-life of VISKEN® is 3 to 4 hours and the drug has a systemic clearance of between 400 and 500 mL/min. Approximately, 40% of pindolol is bound to plasma proteins. Pindolol is extensively and rapidly distributed throughout the body with a mean volume of distribution of 2-3 L/kg. The elimination kinetics has generally been described as a mono-exponential decay function using one compartment pharmacokinetics.

Pindolol is partially metabolized in the liver with approximately 30 to 40% of an oral dose being excreted unchanged in the urine. The remaining 60 to 70% of pindolol is metabolized in the liver forming inactive metabolites - hydroxylate, which is excreted via kidney and liver as glucuronides and ethereal sulfate. The inactive polar metabolites are excreted out with elimination half-life of 8 h. The fraction eliminated in bile is approximately 6-8%.

Approximately 80% of an oral dose is accounted for in the urine within 24 hours.

**INDICATIONS**

a) **Hypertension**

VISKEN® (pindolol) is indicated for the treatment of mild to moderate hypertension. VISKEN® is usually used in combination with other drugs, particularly a thiazide diuretic. However, it may be used alone as an initial agent in those patients in whom, in the judgment of the physician, treatment should be started with a β-blocker rather than a diuretic.

The combination of VISKEN® with a diuretic and/or peripheral vasodilator has been found to be compatible and generally more effective than VISKEN® alone. Limited experience with other antihypertensive agents, including methyldopa, has not shown evidence of incompatibility with VISKEN®.
VISKEN® is not recommended for the emergency treatment of hypertensive crises.

b) **Angina Pectoris**

VISKEN® is indicated for the prophylaxis (prevention) of angina pectoris.

**CONTRAINDICATIONS**

VISKEN® (pindolol) should not be used in the presence of:

1. sinus bradycardia (< 45-50 beats/min)
2. second and third degree A-V block
3. right ventricular failure secondary to pulmonary hypertension
4. congestive heart failure (see WARNINGS)
5. cardiogenic shock
6. anesthesia with agents which produce myocardial depression, e.g. ether
7. bronchospasm, including bronchial asthma or severe chronic obstructive pulmonary disease (see PRECAUTIONS).
8. hypersensitivity to pindolol, to any of the excipients or cross-sensitivity to other beta blockers
9. prinzmetal's angina (variant angina)
11. sick sinus syndrome
12. severe peripheral arterial circulatory disturbances
13. untreated pheochromocytoma

**WARNINGS**

a) **Cardiac Failure:**

Special caution should be exercised when administering VISKEN® (pindolol) to patients with a history of heart failure. Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and inhibition with β-blockade always carries the potential hazard of further depressing myocardial contractility and precipitating
cardiac failure. VISKEN® may reduce but does not abolish the inotropic action of digitalis on the heart muscle. However, the positive inotropic action of digitalis may be reduced by the negative inotropic effect of VISKEN® when the two drugs are used concomitantly. The effects of β-blockers and digitalis are additive in depressing AV conduction. In patients without a history of cardiac failure, continued depression of the myocardium over a period of time can, in some cases, lead to cardiac failure. Therefore, at the first sign or symptom of impending cardiac failure, patients should be fully digitalised and/or given a diuretic and the response observed closely. If cardiac failure continues, despite adequate digitalization and diuretic therapy, VISKEN® should be immediately withdrawn.

b) Abrupt Cessation of Therapy with VISKEN®:
Patients with angina should be warned against abrupt discontinuation of VISKEN®. There have been reports of severe exacerbation of angina, and of myocardial infarction or ventricular arrhythmias occurring in patients with angina pectoris, following abrupt discontinuation of β-blocker therapy. The last two complications may occur with or without preceding exacerbation of angina pectoris. Therefore, when discontinuation of VISKEN® is planned in patients with angina pectoris, the dosage should be gradually reduced over a period of about two weeks and the patient should be observed carefully. The same frequency of administration should be maintained. In situations of greater urgency, VISKEN® therapy should be discontinued stepwise under very close observation.

If angina markedly worsens or acute coronary insufficiency develops, it is recommended that treatment with VISKEN® be reinstituted promptly, at least temporarily.

c) Various skin rashes and conjunctival xerosis have been reported with β-blockers, including VISKEN®. A severe oculo-mucocutaneous syndrome, whose signs include conjunctivitis sica and psoriasiform rashes, otitis, and sclerosing serositis, has occurred with the chronic use of one β-adrenergic-blocking agent (practolol). This syndrome has not been observed with VISKEN®. However, physicians should be alert to the possibility of such reactions and should discontinue treatment in the event that they occur. A switch to another therapeutic agent might be advisable.
d) Sinus bradycardia may occur with the use of VISKEN® due to unopposed vagal activity remaining after blockade of β₁-adrenergic receptors. However, due to its intrinsic sympathomimetic activity (ISA), VISKEN® causes less bradycardia at rest than some other β-adrenergic blocking agents. If excessive bradycardia occurs the dosage of VISKEN® should be reduced.

e) In patients with thyrotoxicosis, possible deleterious effects from long-term use of VISKEN® have not been adequately appraised. β-blockade may mask the clinical signs of continuing hyperthyroidism or complications, and give a false impression of improvement. Therefore, these patients should be carefully monitored for thyroid function. Abrupt withdrawal of VISKEN® may be followed by an exacerbation of the symptoms of hyperthyroidism, including thyroid storm.

f) **Co-medication with calcium channel blockers:** Owing to the danger of cardiac arrest, a calcium channel blocker of the verapamil type must not be administered intravenously to a patient already receiving treatment with a beta-blocker.

g) **Psoriasis:** Since beta-blockers may aggravate psoriasis, VISKEN® should only be prescribed after careful consideration of benefits and risks in patients with history of psoriasis.

**PRECAUTIONS**

a) Caution should be exercised in patients prone to non-allergic bronchospasm (e.g. chronic bronchitis, emphysema) since VISKEN® (pindolol) may block bronchodilation produced by endogenous and exogenous catecholamine stimulation of β-receptors.

b) VISKEN® should be administered with caution to patients with allergic rhinitis prone to bronchospasm.

There may be increased difficulty in treating an allergic type reaction in patients on β-blockers.
In these patients, the reaction may be more severe due to pharmacologic effects of the β-blockers and problems with fluid changes. Epinephrine should be administered with caution since it may not have its usual effects in the treatment of anaphylaxis. On the one hand, larger doses of epinephrine may be needed to overcome the bronchospasm, while on the other, these doses can be associated with excessive alpha-adrenergic stimulation with consequent hypertension, reflex bradycardia and heart block and possible potentiation of bronchospasm. Alternatives to the use of large doses of epinephrine include vigorous supportive care such as fluids and the use of β-agonists, including parenteral salbutamol or isoproterenol, to overcome bronchospasm and norepinephrine to overcome hypotension.

c) VISKEN® should be administered with caution to patients subject to spontaneous hypoglycemia, or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. β-adrenergic-blockers may mask the premonitory signs and symptoms (e.g. palpitations, tachycardia, tremor) of acute hypoglycemia whereas sweating is not inhibited. The concurrent use of beta-blockers and antidiabetic medication should always be monitored to confirm that diabetic control is well maintained.

d) VISKEN® dosage should be individually adjusted when used concomitantly with other antihypertensive agents. (See DOSAGE AND ADMINISTRATION)

c) Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored because the added β-adrenergic-blocking action of VISKEN® may produce an excessive reduction of sympathetic activity. VISKEN® should not be combined with other β-blockers.

f) Appropriate laboratory tests should be performed at regular intervals during long-term treatment.

g) The management of patients being treated with β-blockers and undergoing elective or emergency surgery is controversial. Although β-adrenergic-receptor-blockade impairs the ability of the heart to respond to β-adrenergically-mediated reflex stimuli, abrupt
discontinuation of therapy with VISKEN® may be followed by severe complications (see WARNINGS).

Some patients receiving β-adrenergic-blocking agents have been subject to protracted severe hypotension during anesthesia. Difficulty in re-starting and maintaining the heart beat has also been reported.

For these reasons, in patients with angina, undergoing elective surgery, VISKEN® should be withdrawn gradually following the recommendation given under Abrupt Cessation of Therapy (see WARNINGS). According to available evidence, all clinical and physiological effects of β-blockade are not longer present 48 hours after cessation of medication.

In emergency surgery, since VISKEN® is a competitive inhibitor of β-adrenergic-receptor agonists, its effects may be reversed by sufficient doses of such agonists as isoproterenol or levarterenol.

h) **Impaired Renal or Hepatic Function:** β-blocking agents should be used with caution in patients with impaired hepatic or renal function. Poor renal function has only minor effects on VISKEN® clearance, but poor hepatic function may cause blood levels of VISKEN® to increase substantially.

In patients with severe renal impairment, further impairment of renal function has been only rarely observed during therapy with VISKEN®.

i) **Anaphylactic reaction:** Anaphylactic reactions precipitated by other agents may be particularly severe in patients taking beta-blockers, especially non-selective beta-blockers, and may be resistant to normal doses of adrenaline. Whenever possible, beta-blockers should be avoided in patients who are at increased risk for anaphylaxis.

j) **Pheochromocytoma:** If patients with pheochromocytoma are treated with a beta-blocker, an alpha-blocker should always be co-administered. (see CONTRAINDICATIONS)

k) **Usage in Pregnancy:** Since VISKEN® has not been studied in human pregnancy, the drug should not be given to pregnant women. The use of any drug in patients of
child-bearing potential requires that the anticipated benefit be weighed against possible hazards. Pindolol crosses the placental barrier.

l) **Lactating Women**: Pindolol passes in small quantities into breast milk.

m) **Fertility**: In rats, VISKEN® (pindolol) did not cause any adverse effects on fertility or reproductive performance at a dose of 10 mg/kg, which is 17-times the human dose. While effects in animals are not always predictive of human effects, at dose levels of 30 mg/kg and greater, female rats were observed to mate less frequently than untreated animals (see TOXICOLOGY).

n) **Usage in Children**: Since there is no experience with VISKEN® in the treatment of pediatric age groups, VISKEN® is not indicated for paediatrics.

o) **Usage in Geriatric patients**: No evidence exists that geriatric patients require different dosages; however, these patients should be treated cautiously. An excessive decrease in blood pressure or pulse rate may reduce blood supply to vital organs to inadequate levels.

p) Because dizziness or fatigue may occur during initiation of treatment with β-adrenoreceptor blocking drugs, patients driving vehicles or operating machinery should exercise caution until they have determined their individual response to treatment.

**ADVERSE REACTIONS**

Cardiovascular
Congestive heart failure (see WARNINGS), severe bradycardia (see WARNINGS), may occur. Syncope, lightheadedness, and postural hypotension. Lengthening of PR interval, second degree AV block, palpitation, chest pains, cold extremities, Raynaud's phenomenon, claudication, hot flushes. Very rarely arrhythmia, coronary insufficiency.

Central Nervous System
Insomnia, nightmares, vivid dreams, fatigue, drowsiness, weakness, dizziness, vertigo, tinnitus, headache, mental depression, nervousness. The following adverse reactions have been reported rarely: aggressiveness, motor disorders, confusion.
Gastrointestinal
Diarrhea, constipation, flatulence, heartburn, nausea and vomiting, abdominal pain and dry mouth.

Respiratory
Shortness of breath and/or dyspnea, wheezing, bronchospasm.

Allergic, Dermatological (see WARNINGS)
Exanthema, sweating, pruritis, psoriasiform rash.

Eyes
Itching, burning, grittiness, dryness.

Miscellaneous
Muscle cramps, appetite stimulation, weight gain, urinary frequency.

Clinical Laboratory
On rare occasions, changes in the following parameters were noted: elevated transaminases, alkaline phosphatase, LDH, serum uric acid; reduced bilirubin.

Post-Market Adverse Drug Reactions
The following adverse drug reactions are, in most cases, mild and transient in nature and necessity for interruption of VISKEN® therapy is rarely observed (see WARNINGS and PRECAUTIONS).

These adverse drug reactions (table 1) have been derived from post-marketing experience with VISKEN®. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known. Adverse drug reactions are listed according to system organ classes in MedDRA. Within each system organ class, ADRs are presented in order of decreasing seriousness.
Table 1  Adverse drug reactions (frequency not known)

<table>
<thead>
<tr>
<th>Psychiatric disorders</th>
<th>Sleep disorders, depression, hallucinations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nervous system disorders</td>
<td>Tremor, dizziness, headache</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Bradycardia, conduction disorder, cardiac failure</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Hypotension, symptoms of peripheral vascular disorders (peripheral coldness), Raynaud’s-like symptoms</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Bronchospasm, dyspnea</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Gastrointestinal disorders (nausea, vomiting, abdominal pain and diarrhea)</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Skin reaction, hyperhidrosis, worsening of psoriasis</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Muscle cramps</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Fatigue</td>
</tr>
</tbody>
</table>
DRUG INTERACTIONS

Table form preferred (see HC’s PM guidance for industry)

Table 2 - Established or Potential Drug-Drug Interactions

<table>
<thead>
<tr>
<th>Product</th>
<th>Ref</th>
<th>Effect</th>
<th>Clinical comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monoamine oxidase (MAO) inhibitors</td>
<td>C, T</td>
<td>Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity. Possibly significant hypertension may theoretically occur up to 14 days following discontinuation of the MAO inhibitor</td>
<td>Monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Concurrent use with beta-blockers is not recommended.</td>
</tr>
<tr>
<td>Antidiabetic agents</td>
<td>T</td>
<td>Beta-blockers may interfere with the usual hemodynamic response to hyperglycaemia and produce a rise in blood pressure associated with severe bradycardia.</td>
<td>Beta-blockade reduces the release of insulin in response to hyperglycaemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. Beta-blockers should be avoided in unstable diabetic patients (patients who experience wide and unpredictable fluctuations of blood glucose values and/or difficulty in stabilizing blood glucose levels) prone to episodes of hypoglycemia (see WARNINGS and PRECAUTIONS).</td>
</tr>
<tr>
<td>Product</td>
<td>Ref</td>
<td>Effect</td>
<td>Clinical comment</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>---------</td>
<td>------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Calcium-channel blocking agents</td>
<td>CT</td>
<td>Because of their potential effect on the cardiac conduction system and contractility, the i.v. route must be avoided. Oral treatment, if judged absolutely necessary, requires careful monitoring, especially when the beta-blocker is combined with a verapamil-type calcium antagonist.</td>
<td>Severe reduction in blood pressure and heart failure upon the concomitant administration of dihydropyridine derivatives such as nifedipine with pindolol in patients with latent cardiac insufficiency is possible.</td>
</tr>
<tr>
<td>Anti-adrenergic agents</td>
<td>T</td>
<td>Antihypertensive effect of alpha-adrenergic blockers such as guanethidine, betanidine, reserpine, alpha-methylidopa or clonidine may be potentiated by beta-blockers, which may lead to postural hypotension.</td>
<td>When therapy is discontinued in patients receiving a beta-blocker and clonidine concurrently, the beta-blockers should be gradually discontinued several days before clonidine is discontinued, in order to reduce the potential risk of a clonidine withdrawal hypertensive crisis (rebound effect). Monitoring of blood pressure is recommended during the anti-adrenergics withdrawal.</td>
</tr>
<tr>
<td>Non-steroidal anti-inflammatory drugs (NSAIDs)</td>
<td>T</td>
<td>Concomitant administration of non-steroidal anti-inflammatory drugs including COX-2 inhibitors with a beta-blocker, may decrease its antihypertensive effect, possibly as a result of the inhibition of renal prostaglandin synthesis and sodium and fluid retention caused by NSAIDs.</td>
<td>Anti-hypertensive effects of beta-blockers may be decreased by non-steroidal anti-inflammatory drugs, which may lead to uncontrolled hypertension. Monitoring is required.</td>
</tr>
<tr>
<td>Product</td>
<td>Ref</td>
<td>Effect</td>
<td>Clinical comment</td>
</tr>
<tr>
<td>--------------------</td>
<td>-----</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Phenothiazines</td>
<td>CT</td>
<td>Concurrent administration of pindolol and thioridazine is reported to result in a moderate increases in the serum levels of thioridazine and two of its metabolites, as well as higher than expected serum pindolol levels.</td>
<td>Concurrent use with beta-blockers with phenothiazines results in an increased plasma concentration of either drug, which may lead to hypotension, ventricular tachycardia, and pigmentary retinopathy. Monitoring is required.</td>
</tr>
<tr>
<td>Sympathomimetic drugs</td>
<td>T</td>
<td>Concomitant administration of sympathomimetic drugs such as adrenaline, noradrenaline, isoprenaline, ephedrine, phenylephrine phenylpropanolamine, or xanthine derivatives with a non-selective beta-blocker may enhance the pressor response resulting in severe hypertension due to antagonistic effects.</td>
<td>Pindolol may antagonize the effects of sympathomimetic drugs and xanthine derivatives which may lead to severe hypertension. Monitoring is required.</td>
</tr>
<tr>
<td>Anesthetic agents</td>
<td>CT</td>
<td>Beta-blockers and certain anaesthetics may be additive in their cardio-depressant effect and may lead to protracted severe hypotension (see WARNINGS and PRECAUTIONS).</td>
<td>Anaesthetic agents causing myocardial depression, such as cyclopropane and trichloroethylene, are best be avoided.</td>
</tr>
<tr>
<td>Product</td>
<td>Ref</td>
<td>Effect</td>
<td>Clinical comment</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-----</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Anti-arrhythmic agents</td>
<td>CT</td>
<td>Concomitant administration of beta-blockers with class I anti-arrhythmic agents such as disopyramide, tocainide, flecainide or amiodarone have a potentiating effect on atrial-conduction time and induce negative inotropic effect, which may lead to myocardial depression, cardiac failure, hypotension, bradycardia, AV block and asystole.</td>
<td>Although this potentiation effect is weak for pindolol, the possibility of interactions with anti-arrhythmic agents can not be eliminated. Monitoring is required.</td>
</tr>
<tr>
<td>Digitalis glycosides</td>
<td>T</td>
<td>Beta-blockers and digitalis glycosides may be additive in their depressant effect on myocardial conduction, particularly through the atrioventricular node.</td>
<td>Concomitant administration of digitalis glycosides may induce serious bradycardia or heart block and thus should be avoided.</td>
</tr>
<tr>
<td>Ergot alkaloid</td>
<td>T</td>
<td>Administration with beta-blockers may enhance the vasoconstrictive effect of ergot alkaloids.</td>
<td>Concomitant administration with beta-blockers with ergot alkaloid may enhance the vasoconstriction, which leads to hypertension.</td>
</tr>
<tr>
<td>Product</td>
<td>Ref</td>
<td>Effect</td>
<td>Clinical comment</td>
</tr>
<tr>
<td>-----------</td>
<td>-----</td>
<td>------------------------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>CT</td>
<td>Cimetidine is a moderate inhibitor of multiple cytochrome enzymes such as CYP2D6, CYP3A4, CYP2C19, CYP2E1, CYP2C9, and CYP1A2. Concomitant administration of cimetidine may inhibit the hepatic metabolism of pindolol resulting in increased plasma concentrations of pindolol, which may lead to hypotension.</td>
<td>Monitoring is required.</td>
</tr>
</tbody>
</table>

Legend: C = Case Study; CS = Clinical Study; T = Theoretical

**SYMPTOMS AND TREATMENT OF OVERDOSE**

An overdose of beta-blocker may lead to pronounced bradycardia, hypotension, cardiac failure, cardiogenic shock, conduction abnormalities, cardiac arrest, dyspnea, bronchospasm, vomiting, hypoglycemia, depressed levels of consciousness, generalized convulsions, coma and death. In rare circumstances, overdose of beta-blockers with intrinsic sympathomimetic activity (ISA), like VISKEN®, may present with tachycardia and hypertension. Concomitant ingestion of alcohol, antihypertensives, antidepressants, or antiarrhythmic may aggravate the signs and symptoms of overdose.

If overdose occurs, in all cases therapy with VISKEN® (pindolol) should be discontinued and the patient observed closely. If required, the following therapeutic measures are suggested:

1. Bradycardia: atropine or another anticholinergic drug.
2. Heart block (second or third degree): isoproterenol or transvenous cardiac pacemaker.
4. Hypotension: (depending on associated factors) epinephrine rather than isoproterenol or norepinephrine may be useful in addition to atropine and digitalis (see PRECAUTIONS concerning the use of epinephrine).
5. Bronchospasm: aminophylline or isoproterenol.
6. Hypoglycemia: intravenous glucose.

It should be remembered that VISKEN® is a competitive antagonist of isoproterenol and hence large doses of isoproterenol can be expected to reverse many of the effects of excessive doses of VISKEN®. However, the complications of excess isoproterenol should not be overlooked.

**DOSAGE AND ADMINISTRATION**

a) Hypertension

VISKEN® (pindolol) is usually used in conjunction with other antihypertensive agents, particularly a thiazide diuretic but may be used alone (see INDICATIONS).

VISKEN® should be taken with meals.

The dosage of VISKEN® must always be adjusted to the individual requirements of the patients in accordance with the following guidelines:

VISKEN® therapy should be initiated with doses of 5 mg in the morning with breakfast and 5 mg with the evening meal. If an adequate response is not achieved after one to two weeks, the dose should be increased to 10 mg twice a day.

If after one to two additional weeks an adequate response is not observed, dosage may be increased to 15 mg twice a day (30 mg/day).

Doses greater than 30 mg daily must be given on a t.i.d. schedule.

Patients who show a satisfactory response to VISKEN® at daily doses of 10 to 20 mg may be maintained by giving the required total dose once daily in the morning with breakfast.

The usual maintenance dose is within the range of 15 to 45 mg daily which should not be exceeded. However, during long-term therapy, some patients may be maintained on smaller doses of VISKEN®.
b) **Angina Pectoris**

The dosage of VISKEN® must always be adjusted to the individual requirements of the patient.

In angina, VISKEN® should be administered on a three or four times per day dosing regimen. VISKEN® therapy should be initiated with doses of 5 mg three times a day taken with meals. If after one to two weeks an adequate response is not observed, dosage may be increased. The usual maintenance dose is 15 mg up to the maximum of 40 mg per day.

**Special populations:**

**Patients with impaired renal function/ hepatic function**

Patients with impaired renal or hepatic function may usually be treated with normal doses. Only in severe cases may a reduction of the daily dose be necessary (see PHARMACOLOGY – Special Populations).

**Pediatric patients**

Since the efficacy and safety of VISKEN® has not been established in children, VISKEN® is not indicated for paediatrics.

**Geriatric patients**

No evidence exists that geriatric patients require different dosages; however these patients should be treated cautiously. (see PRECAUTIONS and PHARMACOLOGY – Special Populations)
PHARMACEUTICAL INFORMATION

Trade Name: VISKEN®

Proper Name: pindolol tablets U.S.P.

Chemical Name: 4-(2-hydroxy-3-isopropylaminopropoxy)-indole

Structural Formula:

```
\begin{center}
\includegraphics[width=0.5\textwidth]{structural_formula.png}
\end{center}
```

Molecular Formula: \( \text{C}_{14}\text{H}_{20}\text{N}_{2}\text{O}_{2} \)

Molecular Weight: 248.3

Description: VISKEN® is the free base of pindolol. It is a white, odourless powder soluble in methanol and acetic acid.

Stability and Storage Recommendations: Protect from light.
AVAILABILITY

VISKEN® 5 mg: Each whitish, compressed tablet, 7 mm in diameter, slope faced, bisected with "LB" embossed on one side and flat faced, beveled edge with "VISKEN* 5" embossed on reverse side, contains: pindolol 5 mg. Also contains starch. Bottles of 100 and 500.

VISKEN® 10 mg: Each whitish, compressed tablet, 8 mm in diameter, slope faced, bisected on one side and flat faced, beveled edge with "VISKEN* 10" embossed on reverse side, contains: pindolol 10 mg. Also contains starch. Bottles of 100 and 500.

VISKEN® 15 mg: Each whitish, compressed tablet, 9 mm in diameter, slope faced, bisected with "JU" embossed on one side and flat faced, beveled edge with "VISKEN* 15" embossed on reverse side, contains: pindolol 15 mg. Also contains starch. Bottles of 100.

Non-medicinal Ingredients
Tablets 5 mg, 10 mg and 15 mg: cellulose microcrystalline, pregelatinized starch, magnesium stearate, silica colloidal anhydrous.

PHARMACOLOGY

Effects on the Cardiovascular System
Pindolol, in the non-anesthetized dog, produced a 70% inhibition of tachycardia and changes in blood pressure induced by isoproterenol at doses of 0.05 mg/kg i.v. and 2 mg/kg i.v. respectively. Complete antagonism was observed following pindolol at doses of 0.1 to 5 mg/kg i.v. In the anesthetized dog, 0.2 to 2.0 mg/kg i.v. produced dose dependent decreases in blood pressure; heart rate changes were unrelated to dose and were reduced by 12% after a dose of 0.2 mg/kg i.v. and 4% after i.v. injection of 2 mg/kg.

In the anesthetized dog, 0.2 to 1 mg/kg i.a. antagonized the vasodilation induced by isoproterenol, whereas transient 25 to 40% reductions in vascular resistance were observed after intra-arterial doses of 50 and 200 mg/kg. Intravenous doses of 2 mg/kg of pindolol elicited peripheral vasodilation and an associated reduction in total peripheral resistance.
In vivo studies on the guinea pig atrium showed that pindolol produced dose dependent antagonism of epinephrine-induced positive inotropy and chronotropy.

In five healthy volunteers given a single oral dose of 10 mg of pindolol, antagonism of isoproterenol-induced tachycardia and changes in blood pressure and heart rate were observed 30 minutes after ingestion and persisted for 24 hours. In ten hypertensive patients receiving pindolol for 16 months in divided doses of 20 to 40 mg, blood pressure reduction was associated with statistically significant reduction in forearm and total systemic vascular resistance at rest and during stress testing. Venous tone was significantly reduced during and after exercise. No significant change was reported in cardiac output following prolonged use (see ACTIONS).

Pindolol has little membrane stabilizing activity being approximately 1/12 that of quinidine in prolonging the relative refractory period of cardiac cells in the isolated guinea pig atrium. A concentration of up to 5% pindolol was devoid of local anesthetic effects when applied to the cornea of the eye.

Pindolol possesses partial agonist (intrinsic sympathomimetic) activity. Long-lasting increases in myocardial activity manifested by positive chronotropic actions were observed following i.v. infusions of pindolol at doses of 0.16 mcg/kg to 2.5 mg/kg in the reserpinized, adrenalectomized and vagotomized cat.

Pindolol decreases the basal rate of myocardial oxygen consumption and blocks increases mediated by increased sympathetic nervous system activity.

Pindolol has antiarrhythmic activity. At doses of 8 mg/kg in the anesthetized dog, pindolol increased the dose of ouabain required to produce ventricular arrhythmia. In guinea pigs and dogs, it delayed the onset of ouabain-induced ventricular arrhythmia and in the dog produced reversion to sinus rhythm.

Pindolol has been reported to reduce plasma renin activity in some patients. However, plasma renin may remain unchanged or increase following treatment. There does not appear to be any significant relationship between the antihypertensive activity of pindolol and changes in plasma renin activity.
Effects on Pulmonary Function
In a study of 58 hypertensive patients with normal respiratory function who received oral doses of 15, 30, or 60 mg of pindolol, no significant changes were observed in forced expiratory volume (FEV), maximum voluntary ventilation rate, maximum expiratory flow rate and maximum mid-expiratory flow rate.

Decreased FEV\textsubscript{1} has, however, been reported in other studies.

Other Effects
Electroencephalographic changes, following oral doses of 5 and 10 mg in healthy volunteers, consisted of theta and fast beta and decreases in alpha activity. In rats given 5.2 mg/kg s.c., pindolol blocked tetrabenazine-induced ptosis but not catalepsy. In mice at doses of 1 to 30 mg/kg i.v., pindolol antagonized reserpine-induced hypothermia.

Special populations

Geriatrics
The elderly population may show higher plasma concentrations of pindolol as a combined result of a decreased metabolism of the drug in elderly population, a decreased hepatic blood flow and a decreased renal elimination.

Pregnancy
The elimination half-life of pindolol does not differ significantly between pregnant and non-pregnant patients. (see PRECAUTIONS).

Transplacental distribution of pindolol is not stereoselective. Pregnancy may alter the pharmacokinetic disposition of pindolol, suggesting an increase in the distribution volume and total clearance.

Patients with hepatic / renal impairment
Patients with impaired renal or hepatic function may usually be treated with normal doses. Only in severe cases may a reduction of the daily dose be necessary. The plasma half-life of pindolol is increased up to 11.5 hours, depending on severity, in patient with renal impairment and is increased up to 30 hours, depending on severity, in patients with liver cirrhosis.
TOXICOLOGY

a) Acute Toxicity

<table>
<thead>
<tr>
<th>species</th>
<th>Route</th>
<th>LD_{50} mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>i.v.</td>
<td>29 ± 1.2</td>
</tr>
<tr>
<td>Mouse</td>
<td>p.o.</td>
<td>200 ± 22</td>
</tr>
<tr>
<td>Rat</td>
<td>i.v.</td>
<td>35 ± 1.7</td>
</tr>
<tr>
<td>Rat</td>
<td>p.o.</td>
<td>260 ± 36</td>
</tr>
<tr>
<td>Rabbit</td>
<td>i.v.</td>
<td>10 ± 0.9</td>
</tr>
<tr>
<td>Rabbit</td>
<td>p.o.</td>
<td>650 ± 102</td>
</tr>
<tr>
<td>Dog</td>
<td>p.o.</td>
<td>≥ 30</td>
</tr>
</tbody>
</table>
b) Subacute

<table>
<thead>
<tr>
<th>Species /strain</th>
<th>Sex M/F</th>
<th>No. of groups</th>
<th>N/group</th>
<th>Dose mg/kg/day</th>
<th>Route</th>
<th>Duration</th>
<th>Toxic Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>40/40</td>
<td>4</td>
<td>10M/10F</td>
<td>0, 16, 66, 246</td>
<td>Oral</td>
<td>13 weeks</td>
<td>At 246 mg/kg there was a mortality rate of 20%. Arrest of spermatogenesis in males and hypoplastic uteri in females were observed at doses of 66 and 246 mg/kg. Doses of 16, 66 and 246 mg/kg slightly to moderately increased SGPT levels, and reduced food intake, the efficiency of food utilization and organ and body weights. Treated animals had a slightly higher incidence of infection than controls. Granular inclusions in liver and adrenal cells and increased numbers of fat droplets in renal tubule cells were seen at doses of 246 mg/kg. Similar but less prominent changes were found at 66 mg/kg. There were isolated incidences of thymus involution, contraction of the seminal vesicles and prostatic atrophy. Green discolouration of the urine was observed.</td>
</tr>
<tr>
<td>Rats</td>
<td>40/40</td>
<td>4</td>
<td>10M/10F</td>
<td>0, 5, 25, 130</td>
<td>oral</td>
<td>26 weeks</td>
<td>At 130 mg/kg/day, decreased body weight and cyanosis were observed.</td>
</tr>
<tr>
<td>Dogs/ Beagle</td>
<td>8/8</td>
<td>4</td>
<td>2M/2F</td>
<td>0, 5, 20, 80</td>
<td>oral</td>
<td>13 weeks</td>
<td>At 80 mg/kg/day, convulsions, gastrointestinal disturbances, mydriasis, erythema secondary to cutaneous vasodilation were observed. Food intake and body weight were reduced.</td>
</tr>
<tr>
<td>Dogs/ Beagle</td>
<td>12/12</td>
<td>4</td>
<td>3M/3F</td>
<td>0, 5, 15, 45</td>
<td>oral</td>
<td>26 weeks</td>
<td>At 45 mg/kg, the mortality rate was 50%. Hepatocyte swelling, and the presence of intracellular hyaline droplets and lipochrome pigment in hepatocytes and Kupffer cells were seen at 15 and 45 mg/day and a few single sporadic degenerating liver cells were observed. Green discolouration of the urine was seen at 15 and 45 mg/kg/day. One dog in each group given 5, 15, and 45 mg/kg/day showed transient increases in alkaline phosphatase. In the 45 mg/kg/day group, convulsions, gastrointestinal disturbances, arrest of spermatogenesis, weight loss and reduced adreno-cortical lipids were observed.</td>
</tr>
<tr>
<td>Rats</td>
<td>30/30</td>
<td>3</td>
<td>10M/10F</td>
<td>0, 1, 3</td>
<td>i.v.</td>
<td>4 weeks</td>
<td>None</td>
</tr>
</tbody>
</table>
### Chronic Toxicity

<table>
<thead>
<tr>
<th>Species /strain</th>
<th>Sex M/F</th>
<th>No. of groups</th>
<th>N/group</th>
<th>Dose mg/kg/day</th>
<th>Route</th>
<th>Duration (years)</th>
<th>Toxic Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dogs/Beagle</td>
<td>2/2</td>
<td>1</td>
<td>2M/2F</td>
<td>0</td>
<td>i.v.</td>
<td>4 weeks</td>
<td>1.5 mg/kg: Erythema secondary to cutaneous vasodilation</td>
</tr>
<tr>
<td></td>
<td>4/4</td>
<td>2</td>
<td>2M/2F</td>
<td>1.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rats</td>
<td>5/5</td>
<td>1</td>
<td>5M/5F</td>
<td>0</td>
<td>i.m.</td>
<td>4 weeks</td>
<td>5 mg/kg: Slight irritant effect at injection site</td>
</tr>
<tr>
<td></td>
<td>10/10</td>
<td>1</td>
<td>10M/10F</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rats</td>
<td>120/120</td>
<td>4</td>
<td>30M/30F</td>
<td>0, 2, 14, 98</td>
<td>oral</td>
<td>2</td>
<td>Green discolouration of the urine at 98 m/kg. At 2, 14 and 98 mg/kg, deposition of a greenish brown pigment in Kupffer cells of the liver.</td>
</tr>
<tr>
<td>Dogs/Beagle</td>
<td>16/16</td>
<td>4</td>
<td>4M/4F</td>
<td>0, 2, 6, 18</td>
<td>oral</td>
<td>2</td>
<td>Tachycardia of 1 week duration. Erythema secondary to cutaneous vasodilatation which was not dose dependent. Emesis and soft stools.</td>
</tr>
<tr>
<td>Monkey/Rhesus</td>
<td>9/9</td>
<td>3</td>
<td>3M/3F</td>
<td>0, 2.5, 25</td>
<td>oral</td>
<td>1</td>
<td>At 2.5 mg/kg, heart rate was slowed 15 to 20%. Bradycardia was seen at 25 mg/kg. Green discolouration of the urine at 25 mg/kg.</td>
</tr>
</tbody>
</table>
d) Disposition of Pigment
Oral administration of pindolol to rats at a dose of 200 mg/kg/day for 26 weeks resulted in the deposition of a melanin-like pigment in the liver, spleen, adrenal gland and subcutaneous tissue. Partial disappearance of this pigment from Kupffer cells in the liver occurred within four weeks following discontinuation of pindolol.

In dogs given oral doses of 5, 15, and 45 mg/kg/day for 26 weeks, dose related increases in hepatocyte lipid content were observed.

However, despite the pigment deposition and increased lipid content, all tests done for hepatic, splenic and adrenal function were normal. The significance of pigment and lipid changes is unknown.

e) Teratology and Reproduction Studies
i) Teratology
The parameters studied in the rat and rabbit teratology studies were the following: total number of pregnancies, implantations, viable fetuses, dead fetuses, total prenatal deaths, abnormal fetuses in % of living fetuses.

Rat:
Doses of 30 and 100 mg/kg were administered orally to groups of 20 pregnant rats (Sandoz Closed Strain) on days 7-16 of gestation. Treatment with pindolol did not adversely affect any of the parameters studied.

Rabbit:
Doses of 8, 23 and 80 mg/kg were administered orally to groups of respectively, 13, 16 and 15 pregnant rabbits (Swiss Hare Strain) on days 6-18 of gestation. None of the parameters studied was significantly affected.
ii) Reproduction

Rat: Doses of 10, 30 and 100 mg/kg were administered orally to groups of 15 male (Sandoz Closed Strain) and 30 female (Carworth Wistar CFE Strain) rats. Males were treated for 70 days prior to and during the mating period. The females were treated for up to 15 days prior to mating, during mating, and throughout the gestation and lactation period to 21 days postpartum, with an interim sacrifice at Day 13 of gestation.

Spermatogenesis and fertility were reduced at doses of 30 but not 100 mg/kg/day. Tubular atrophy in the testes was found in male rats treated with doses of 30 and 100 mg/kg/day.

There was significantly greater mortality in the offspring of females treated with 100 mg/kg/day in the first four-day postpartum period and in pups of females receiving 30 mg/kg/day during the 4 to 21-day postpartum interval. This increased mortality may be consequence of deficits in maternal rearing behaviour, inhibition of lactation or the presence of the drug in maternal milk.

f) Carcinogenicity Studies

Mouse: Pindolol was administered to 50 male and 50 female mice (Sandoz OFI Strain) at dietary levels of approximately 124 mg/kg/day for 82 weeks, with an equal number of mice serving as controls. The incidence of nodules and masses observed at necropsy were comparable in the treated and control groups. This strain of mice was previously shown to be susceptible to chemical carcinogenesis.

Rat: Pindolol was administered to 50 male and 50 female rats (Sandoz OFA Strain) at a mean dose of 50 mg/kg/day for 83 weeks. A similar group of 100 rats served as a control. Mortality and incidence of tumor were comparable in the treated and untreated groups. This strain of rat was previously shown to be susceptible to chemically (2AAF) induced carcinogenesis.
BIBLIOGRAPHY


DATA ON FILE

32. Data on file - Medical Services Department, Novartis Pharmaceuticals Canada Inc., 385 Bouchard Blvd., Dorval, Que., H9S 1A9.

32.A Loew D. Investigations on neuropharmacological effects of LB-46. Sandoz Limited, Basle, Switzerland, 20.1.70, see above.